Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

DA 8031

Known as: DA-8031, DA8031 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objective DA-8031 is a selective serotonin reuptake inhibitor under development for the treatment of premature ejaculation. This… Expand
  • figure 1
  • figure 2
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2016
Review
2016
Objective To review potential therapeutic targets and future therapeutic molecules in premature ejaculation (PE). PE is the most… Expand
Is this relevant?
Review
2016
Review
2016
OBJECTIVE To review potential therapeutic targets and future therapeutic molecules in premature ejaculation (PE). PE is the most… Expand
Is this relevant?
2014
2014
OBJECTIVE To investigate the efficacy of DA-8031, a novel compound for the treatment of premature ejaculation, we measured… Expand
Is this relevant?
2014
2014
DA‐8031 is a potent and selective serotonin transporter inhibitor developed for the treatment of premature ejaculation. The aim… Expand
Is this relevant?
2013
2013
OBJECTIVE To investigate the efficacy of DA-8031, a novel compound for the treatment of premature ejaculation (PE), we performed… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
2011
2011
OBJECTIVES To evaluate the efficacy of DA-8031 against premature ejaculation, we performed in vitro and in vivo pharmacologic… Expand
Is this relevant?